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Summary
Background The Global Enteric Multicenter Study (GEMS) was a 3-year case-control study that measured the burden, 
aetiology, and consequences of moderate-to-severe diarrhoea (MSD) in children aged 0–59 months. GEMS-1A, 
a 12-month follow-on study, comprised two parallel case-control studies, one assessing MSD and the other less-severe 
diarrhoea (LSD). In this report, we analyse the risk of death with each diarrhoea type and the specific pathogens 
associated with fatal outcomes.
Methods GEMS was a prospective, age-stratified, matched case-control study done at seven sites in Africa and 
Asia. Children aged 0–59 months with MSD seeking care at sentinel health centres were recruited along with one 
to three randomly selected matched community control children without diarrhoea. In the 12-month GEMS-1A 
follow-on study, children with LSD and matched controls, in addition to children with MSD and matched controls, 
were recruited at six of the seven sites; only cases of MSD and controls were enrolled at the seventh site. We 
compared risk of death during the period between enrolment and one follow-up household visit done about 
60 days later (range 50–90 days) in children with MSD and LSD and in their respective controls. Approximately 
50 pathogens were detected using, as appropriate, classic bacteriology, immunoassays, gel-based PCR and 
reverse transcriptase PCR, and quantitative real-time PCR (qPCR). Specimens from a subset of GEMS cases 
and controls were also tested by a TaqMan Array Card that compartmentalised probe-based qPCR for 
32 enteropathogens.
Findings 223 (2·0%) of 11 108 children with MSD and 43 (0·3%) of 16 369 matched controls died between study 
enrolment and the follow-up visit at about 60 days (hazard ratio [HR] 8·16, 95% CI 5·69–11·68, p<0·0001). 12 (0·4%) 
of 2962 children with LSD and seven (0·2%) of 4074 matched controls died during the follow-up period (HR 2·78, 
95% CI 0·95–8·11, p=0·061). Risk of death was lower in children with dysenteric MSD than in children with non-
dysenteric MSD (HR 0·20, 95% CI 0·05–0·87, p=0·032), and lower in children with LSD than in those with non-
dysenteric MSD (HR 0·29, 0·14–0·59, p=0·0006). In children younger than 24 months with MSD, infection with 
typical enteropathogenic Escherichia coli, enterotoxigenic E coli encoding heat-stable toxin, enteroaggregative E coli, 
Shigella spp (non-dysentery cases), Aeromonas spp, Cryptosporidium spp, and Entamoeba histolytica increased risk of 
death. Of 61 deaths in children aged 12–59 months with non-dysenteric MSD, 31 occurred among 942 children qPCR-
positive for Shigella spp and 30 deaths occurred in 1384 qPCR-negative children (HR 2·2, 95% CI 1·2–3·9, p=0·0090), 
showing that Shigella was strongly associated with increased risk of death.
Interpretation Risk of death is increased following MSD and, to a lesser extent, LSD. Considering there are 
approximately three times more cases of LSD than MSD in the population, more deaths are expected among children 
with LSD than in those with MSD. Because the major attributable LSD-associated and MSD-associated pathogens are 
the same, implementing vaccines and rapid diagnosis and treatment interventions against these major pathogens are 
rational investments.
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Introduction
The fourth Millennium Development Goal (MDG4), 
which aimed to reduce mortality in children younger 
than 5 years by two-thirds by 2015 compared with the 
1990 baseline, triggered efforts to improve monitoring 
and to identify the predominant causes of paediatric 
deaths.1,2 Although in 1990 south Asia’s enormous annual 
birth cohort contributed the largest number of deaths 
in children younger than 5 years (4·78 million vs 
3·77 million for sub-Saharan Africa), the highest under-5 
mortality was reported in sub-Saharan Africa (177 per 
1000 livebirths vs 126 per 1000 livebirths in south Asia).1,2 
To achieve MDG4, the major causes of under-5 mortality 
in these two geographical regions had to be reduced 
substantially. Early estimates identified diarr hoeal disease 
as the second most common cause of under-5 mortality 
after pneumonia, accounting for approximately 19% of 
deaths.1,3 Subsequent analyses indicated that under-5 
mortality was falling globally, including the proportion 
of post-neonatal child mortality (age 1–59 months) 
attributable to diarrhoeal disease.4–6
One post-2015 challenge is to accelerate the decrease 
in mortality from diarrhoeal disease so that by 2030 
the overall under-5 mortality will not exceed 25 per 
1000 livebirths in any country worldwide (part of 
Sustainable Development Goal [SDG] 3.2).7 Improved 
treatment of diarrhoeal disease, water and sanitation 
upgrades, and development and introduction of vaccines 
against major diarrhoeal disease agents associated with 
fatality could achieve this ambitious aim. Diarrhoeal 
mortality estimates from the 2016 Global Burden of 
Disease Study8 suggest that this goal is feasible, including 
in sub-Saharan Africa.8,9
The Global Enteric Multicenter Study (GEMS) was 
done in the first decade of the millennium when 
diarrhoeal disease constituted the second most frequent 
cause of under-5 mortality and there was uncertainty 
regarding the relative mortality contribution of specific 
enteric pathogens.10–12 During the last quarter of the 20th 
century, many new diarrhoeal pathogens were identified 
and improved diagnostics in the first decades of the 21st 
century offered high-throughput options with increased 
sensitivity to detect these pathogens in individuals with 
diarrhoeal disease and in controls without diarrhoea.10
The 3-year GEMS case-control study identified aetio-
logical agents associated with moderate-to-severe diarrhoea 
(MSD), assuming that cases of this severity might be fatal 
if the patient could not access health care.11 Children 
with MSD were enrolled at sentinel health centres that 
served demographically monitored populations so that 
pathogen-specific population-based incidence rates could 
be estimated.12–14 Matched controls without diarrhoea were 
selected among children in the community. The study 
reported adjusted attributable fractions for pathogens that 
Research in context
Evidence before this study
Although diarrhoeal-associated deaths have steadily decreased 
during the past two decades, diarrhoeal diseases remain 
responsible for an estimated 9% of all mortality in children 
younger than 5 years, accounting for about 499 000 to 
525 000 annual deaths. Accurate descriptions of the major 
causative pathogens, determinants, and risk factors for these 
deaths are necessary to design improved preventive and 
therapeutic strategies that will have maximal impact on diarrhoeal 
disease, and thus, on young child survival. We searched PubMed 
for articles published in English, Spanish, French, or Portuguese 
between Jan 1, 2000, and Sept 30, 2019, using the terms “low 
and middle-income countries” or “developing countries” AND 
“diarrheal deaths” OR “diarrhea AND mortality”. We included 
earlier reports, and articles identified in reference lists, as 
appropriate. Previous aetiological studies have put the focus on 
specific pathogens in particular high-risk populations, including, 
among others, rotavirus, diarrhoeagenic Escherichia coli, or 
Shigella spp. However, few studies have included comprehensive 
investigation of a representative sample of diarrhoea cases in 
children in different low-income regions of the world where 
diarrhoeal illness remains a major public health problem.
Added value of this study
Data from the GEMS study showed that during the 
approximately 60-day follow-up period, children with MSD had 
an 8·5 times increased risk of death compared with control 
children without diarrhoea. The GEMS-1A study corroborates 
the MSD risk of death (nearly 12 times increase in cases 
compared with controls) and further showed that children with 
LSD had a 2·8 times increased risk of death compared with 
controls, although this difference was not statistically 
significant. Somewhat surprisingly, children with non-
dysenteric MSD had a substantially higher risk of dying than did 
children with dysenteric MSD; notably, most children with 
dysentery in the GEMS and GEMS-1A studies received anti-
Shigella antibiotics in accordance with WHO standard of care 
recommendations. About half the deaths in children aged 
12–59 months with non-dysenteric MSD were positive for 
Shigella spp when quantitative real-time PCR (qPCR) testing was 
performed. Notably, three-quarters of the qPCR-positive fatal 
non-dysenteric MSD cases had negative cultures for Shigella spp. 
Implications of all the available evidence
Collectively, these observations provide a strong rationale for 
vigorously acting upon all severities of diarrhoeal illness. 
Additionally, the prominence of delayed deaths occurring 14 or 
more days after enrolment of cases calls for a need to ensure 
follow-up for several weeks beyond the initial management of 
the acute diarrhoeal episode. The main pathogens implicated in 
MSD-associated or LSD-associated deaths were found to be the 
same, thus supporting the need to pursue common preventive 
and therapeutic strategies for diarrhoea as a major threat to 
child survival.
Articles
www.thelancet.com/lancetgh   Vol 8   February 2020 e206
took into account the presence of enteropathogens in 
matched controls without diarrhoeal disease and adjusted 
for the presence of multiple pathogens.12–15 The GEMS 
study included a single household visit about 60 days after 
enrolment to ascertain the vital status of children with 
MSD and controls, and to assess linear growth since 
enrolment.12,13 Thus, deaths that occurred among cases and 
controls during a prospective 60-day period were captured. 
The GEMS study identified four major pathogens 
associated with MSD (rotavirus, Cryptosporidium spp, 
enterotoxi genic Escherichia coli encoding heat-stable toxin 
[ST-ETEC] with or without co-expression of heat-labile 
enterotoxin, and Shigella spp) and showed that children 
with MSD had more linear growth faltering during the 
follow-up period than did controls.12 The GEMS study also 
showed that during the approximately 60-day follow-up 
period, MSD was associated with an 8·5 times increase 
in the odds of death compared with no diarrhoea.12 
Many deaths in children with MSD occurred at home 
beyond the first week post-enrolment and would have 
been missed were it not for the 60-day visit to case and 
control households.
Children with MSD in the GEMS study accounted for 
only 24·1% of all children with diarrhoeal disease who 
presented to the sentinel health centres; no data were 
obtained from children seeking health care who had the 
more common less-severe diarrhoea (LSD) and who 
were therefore ineligible for enrolment into the GEMS 
study. Accordingly, a 1-year follow-on study, GEMS-1A, 
was done, consisting of two parallel case-control studies, 
one enrolling cases of MSD and matched controls and 
the other enrolling cases of LSD and matched controls.16 
The GEMS-1A study assessed the overall and pathogen-
specific, population-based, attributable incidence and the 
pathogen-specific attributable fraction, and the frequency 
of nutritional faltering in children with the two diarrhoeal 
syndromes. Outcomes were assessed by site and age 
stratum, and across all sites for incidence and nutritional 
outcomes. Because dysentery was an exclusion criterion 
for LSD, in the GEMS-1A study a non-dysentery MSD 
category was included to compare watery diarrhoea 
syndromes of differing severity.
Herein we report deaths in children with MSD (overall, 
dysenteric, and non-dysenteric) during 4 years of 
enrolment; deaths in children with MSD and LSD and in 
their matched controls during the two parallel GEMS-1A 
case-control studies; specific pathogens associated with 
fatal outcomes; deaths in cases and controls over time 
post-enrolment; and insights from verbal autopsies on 
potential causes of delayed diarrhoea-associated deaths.
Methods
Study design and participants
The 12-month GEMS-1A study of MSD and LSD 
used, with minor exceptions,16 the same clinical,13 
epidemiological,11,13 microbiological,17 data management, 
and analytical methods14 as the 3-year GEMS study of MSD.
Six of the original seven GEMS field sites, located in 
countries with moderate-to-high mortality of children 
younger than 5 years in Africa (Mali, Mozambique, 
The Gambia) and Asia (Bangladesh, India, Pakistan) 
participated in the GEMS-1A study; cases of MSD only 
were enrolled in Kenya during GEMS-1A. Each site 
performed a population census and maintained a 
demographic surveillance system (DSS) during the case-
control study to estimate the median population in each 
age stratum.12,13,16 For case enrolment, sentinel health 
centres were selected where children included in the 
DSS sought care for diarrhoeal illnesses, as determined 
by Healthcare Utilization and Attitudes Surveys.18
Children aged 0–59 months belonging to the DSS 
population at each site who sought care at a sentinel 
health centre were screened for diarrhoea, defined as 
three or more loose stools during the previous 24 h. Each 
child with diarrhoea was assessed for eligibility. Episodes 
eligible for inclusion had to be new (onset after 
≥7 diarrhoea-free days), acute (onset within the previous 
7 days), and fulfil at least one of the following criteria for 
MSD: sunken eyes (confirmed by parent or caretaker as 
beyond normal); loss of skin turgor; intravenous hydration 
administered or prescribed; dysentery (visible blood in 
loose stools); or admission to hospital. The remaining 
non-MSD, new, acute diarrhoea episodes were eligible to 
be enrolled as LSD.16 To maintain a manageable work flow 
we enrolled the first eight or nine eligible children with 
MSD and LSD per age stratum per fortnight. Following a 
prespecified algorithm, we aimed to enrol one to three 
control children without diarrhoea for each enrolled MSD 
or LSD case, depending on how many cases were enrolled 
in a fortnight in a particular age-sex stratum at a study 
site;12 in six instances four controls were enrolled. 
Controls, matched to each individual case by age 
(±2 months for cases aged 0–11 months and ±4 months for 
cases aged 12–59 months), sex, and residence (same or 
nearby village or neighbourhood as the case) were 
randomly selected from the site’s DSS database and 
enrolled within 14 days of the case. Potential controls who 
had diarrhoea in the preceding 7 days were ineligible.
Enrolment at GEMS sites began on Dec 1 (India), Dec 2 
(Bangladesh), Dec 10 (The Gambia, Mozambique), and 
Dec 17 (Mali), 2007, Jan 31, 2008 (Kenya), and 
March 3, 2008 (Pakistan), and ended on March 3, 2011. 
GEMS-1A enrolment began on Oct 31, 2011, and ceased 
on Nov 14, 2012.
The clinical protocols for the GEMS and GEMS1-A 
studies were approved by ethics committees at the 
University of Maryland (Baltimore, MD, USA), and at 
every field site. Written informed consent was obtained 
from the parent or primary caretaker of each participant.
Procedures
Study procedures for the GEMS and GEMS1-A studies 
have been described in detail elsewhere.11–13,16,17  Entero-
pathogens were identified in stool specimens collected 
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at baseline from cases and controls.16,17 Approximately 
50 pathogens were detected using, as appropriate, classic 
bacteriology, immunoassays, gel-based PCR and reverse 
transcriptase PCR, and quantitative real-time PCR 
(qPCR).16,17 The laboratory assays used are summarised in 
the clinical protocol (appendix pp 1–49). The GEMS-1A 
PCR methods for detecting E coli pathotypes are included 
in the appendix (pp 50–53). Specimens from a subset of 
GEMS cases and controls were also tested using a 
TaqMan Array Card that compartmentalised probe-based 
qPCR assays for 32 enteropathogens.19
Field workers made a single follow-up visit to 
households of cases and controls about 60 days after 
enrolment (window 50–90 days) to assess the child’s 
vital status, capture interim medical events, and repeat 
anthropometric measurements.13,16 Strictly speaking, 
deaths in cases during the 60-day follow-up period 
constitute an extended case fatality risk,20 while deaths in 
controls during the 60-day period constitute a mortality 
risk. For simplicity, we use the term risk of death for 
both cases and controls.12
When deaths in enrolled children were detected, a time 
was arranged (respecting mourning practices) to perform 
a verbal autopsy using a WHO questionnaire.13 For deaths 
occurring in health centres or hospitals, study-specific 
case report form data were collected to complement 
information gathered via verbal autopsy. Verbal autopsy 
data were reviewed as follows: after standardised training 
was done for all sites by the same person (QB), two local 
clinicians experienced in verbal autopsy and in 
international coding of causes of death independently 
reviewed the verbal autopsy forms and assigned up to two 
plausible causes of death, using the simplified coding 
system based on the International Classification of 
Diseases, 10th revision (ICD-10) recom mended for verbal 
autopsy. If codes assigned by the two reviewers differed, a 
third clinician experienced in verbal autopsy served as 
arbiter to provide a definitive cause of death code.
Statistical analysis
Sample size considerations and justifications have been 
described elsewhere.12 Cumulative risk of death was 
13 128 matched controls
12 833 had 60-day follow-up
37 children died
9439 children with MSD enrolled 
(94·6% of MSD visits)
8952 had 60-day follow-up
190 children died
7963 children with MSD enrolled 
(95·1% of MSD visits)
9976 children with MSD invited 
(67·6% of MSD visits)
8369 children with MSD invited 
(66·0% of MSD visits)
14 753 visits with MSD, 7 sites 
(24·0% of diarrhoea visits)
12 679 visits with MSD, 6 sites 
(21·4% of diarrhoea visits)
61 545 with diarrhoea 
(10·3% of visits)
59 161 with diarrhoea 
(10·9% of visits)
596 519 visits by children aged 
0–59 months to sentinel 
health centres in 7 sites 
(including Kenya)
542 875 visits by children aged 
0–59 months to sentinel 
health centres in 6 sites 
(excluding Kenya)
7173 had 60-day follow-up
138 children died
11 245 matched controls
10 548 had 60-day follow-up
26 children died
4777 not invited 
224 after hours
63 no rectal swab 
1928 inadequate stool 
2207 quota filled
29 died
66 too sick 
260 other 
4310 not invited
216 after hours
60 no rectal swab 
1804 inadequate stool 
1971 quota filled
29 died
40 too sick 
190 other
541 refused to enrol 410 refused to enrol
A
(Figure 1 continues on next page)
See Online for appendix
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calculated by the Kaplan-Meier method. Between-group 
comparisons of risk of death used proportional hazards 
(Cox) regression; when unfeasible because of small 
numbers, simple risk ratios were estimated. When cases 
and their matched controls were compared, the analysis 
was stratified by case-control set.
Cumulative hazard curves from Kaplan-Meier risk of 
death analysis are shown for MSD cases during 4 years of 
enrolment. Pathogens associated with increased risk of 
death in MSD and LSD cases were identified using 
multiple Cox regression. Pathogens were included if 
there were at least five deaths that tested positive for the 
pathogen and if that pathogen was significantly (p<0·10) 
associated with death in crude analyses that controlled 
only for site. Pathogens were then eliminated from a 
model that adjusted for other pathogens until only those 
pathogens significantly (p≤0·05) associated with death 
remained. This model selection method was used in 
GEMS analyses.12,14 Hazard ratios (HRs) and 95% CIs are 
pres ented for all pathogens considered in the crude and 
the final model. Baseline height-for-age or length-for-age 
(HAZ) scores at the Pakistan site versus other Asian 
sites were compared by two-sample t test. Pair-wise 
comparisons were two-sided; results with p values 
of 0·05 or lower were considered significant. We made 
no imputation of missing values or adjustment for 
multiple comparisons. SAS version 9.4 was used for all 
analyses apart from Kaplan-Meier cumulative hazard 
curves, which were estimated using R version 3.5.3.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had final 
respon sibility for the decision to submit for publication.
Results
Figure 1 shows the numbers of enrolled cases and 
controls, the number of households that had a follow-up 
3597 matched controls
3433 had 60-day follow-up
3 children died
2368 children with MSD enrolled 
(63·7% of MSD visits)
2212 had 60-day follow-up
23 children died
3174 children with LSD enrolled 
(28·3% of LSD visits)
2509 children with MSD invited 
(67·5% of MSD visits)
4248 children with LSD invited 
(37·8% of LSD visits)
3718 visits with MSD 
(23·4% of diarrhoea visits)
15 918 with diarrhoea (8·3% of visits)
144 225 child-years of observation
192 086 visits by children aged 0–59 months to sentinel 
health centres in 6 sites (excluding Kenya)
11 225 visits with LSD
(70·5% of diarrhoea visits)
2692 had 60-day follow-up
12 children died
4236 matched controls
4074 had 60-day follow-up
7 children died
1209 not invited
148 after hours
11 no rectal swab
552 inadequate stool
268 quota filled
4 died
22 too sick
204 other
6977 not invited
656 after hours
17 no rectal swab 
2537 inadequate stool
1819 quota filled
1 died
1 too sick
1946 other
141 refused to enrol 1074 refused to enrol
B
(Figure 1 continues on next page)
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visit at about 60 days after enrolment, and deaths in all 
age strata combined for the GEMS study, GEMS-1A 
study, and Kenya during the GEMS-1A study where only 
MSD cases were enrolled. This information is displayed 
by age stratum in the appendix (pp 54–56).
Table 1 and figure 2 show the cumulative hazard of 
death for all MSD cases, non-dysenteric MSD cases, and 
dysenteric MSD cases, and their controls, during the 
60-day post-enrolment period for all seven sites during 
4 years of enrolment. All MSD cases and the MSD case 
subsets (dysentery or non-dysentery) show a significantly 
higher risk of death than their controls. Children with 
non-dysenteric MSD had a substantially higher risk of 
death (2·41 per 100 cases) than did children with dysenteric 
MSD (0·84 per 100 cases; p<0·0001). Table 1 also shows 
MSD deaths and risk of death by age stratum, with the 
heaviest burden in children younger than 24 months.
Of the 223 deaths in children with MSD, 110 (49·3%) 
occurred at least 14 days after enrolment and 79 (35·4%) 
occurred at least 21 days after enrolment. 193 (86·5%) of 
223 deaths in children with MSD and 40 (93·0%) of 
43 deaths in control children occurred in the four African 
sites. Risk of death estimates in controls at Asian sites 
were smaller than those observed at African sites, with 
only one death observed per site in controls during the 
4 years. However, in children with MSD, the Pakistan site 
showed a unique pattern, with 21 deaths, resulting in a 
high HR of 16·00 (95% CI 2·12–120·65; table 1); no other 
Asian site had more than seven deaths in children with 
MSD. Because access to health care and treatment 
regimens were similar at the Asian sites, we hypothesised 
that children with MSD in Pakistan might have been 
more malnourished and thus at increased risk for a fatal 
outcome from MSD. Accordingly, we compared baseline 
HAZ scores in the 1594 children in Pakistan versus the 
3821 children in India plus Bangladesh. Baseline HAZ in 
children in Pakistan (HAZ –2·03, 95% CI –2·10 to –1·95) 
was significantly lower than that in the other south Asian 
children (HAZ –1·31, –1·35 to –1·27; difference between 
means –0·72, 95% CI –0·79 to –0·64, p<0·0001).
In an analysis of data from six sites of the study 
(excluding Kenya), children with MSD were more likely 
to die than their matched controls during the GEMS 
study (HR 8·89, 95% CI 5·55–14·22) and GEMS-1A 
study (HR 11·91, 3·50–40·53; both p<0·0001; table 2). 
Children with dysenteric MSD at these six sites during 
the GEMS-1A study were less likely to die during the 
follow-up period than were children with non-dysenteric 
MSD (HR 0·20, 95% CI 0·05–0·87, p=0·032), as also 
observed during the GEMS study at those six sites 
(HR 0·41, 0·25–0·67, p=0·0003).
Risk of death per 100 cases in the GEMS-1A study was 
significantly higher in children with MSD than in those 
with LSD (HR 2·57, 95% CI 1·28–5·17, p=0·0080; 
table 2). Nonetheless, risk of death was greater in 
children with LSD than in their matched controls, 
although not significantly (HR 2·78, 95% CI 0·95–8·11, 
p=0·061). Because LSD excludes clinical dysentery, we 
compared the risk of death in children with LSD versus 
that in children with non-dysenteric MSD, and found the 
risk of death to be significantly lower in children with 
LSD (HR 0·29, 0·14–0·59, p=0·0006; table 2).
In Cox regression analysis, in all infants aged 
0–11 months with MSD in the GEMS and GEMS-1A 
studies combined, typical enteropathogenic E coli 
(tEPEC), ST-ETEC, and Aeromonas spp infections were 
associated with increased risk of death (table 3), as were 
Cryptosporidium, tEPEC, enteroaggregative E coli, and 
Entamoeba histolytica infection in toddlers aged 
12–23 months; the HR changed only minimally when 
controlled for breastfeeding (exclusive [defined as 
565 matched controls302 children with MSD enrolled 
(91·0% of MSD visits) 
332 with MSD invited (74·9% of 
MSD visits)
443 visits with MSD (60·7% of 
diarrhoea visits)
730 with diarrhoea (5·4% of 
visits)
23 231 child-years of observation
13 399 visits by children aged 
0–59 months to sentinel 
health centres in Kenya
547 had 60-day follow-up
30 refused to enrol
299 had 60-day follow-up
3 children died10 children died
111 not invited
6 no rectal swab 
15 inadequate stool 
25 quota filled
7 too sick
58 other
C
Figure 1: Study profiles for the GEMS and GEMS-1A studies
(A) GEMS study enrolment of children aged 0–59 months with MSD and matched 
controls during 3 years at sentinel health centres at all seven GEMS sites (including 
Kenya) and at six sites (excluding Kenya). (B) GEMS-1A study enrolment of children 
aged 0–59 months during 1 year when cases of MSD, cases of LSD, and matched 
controls were enrolled at sentinel health centres at six sites (excluding Kenya). 
(C) GEMS-1A study enrolment of children aged 0–59 months with MSD and 
matched controls during 1 year at sentinel health centres at the Kenya site (LSD 
cases were not enrolled). MSD=moderate-to-severe diarrhoea. LSD=less-severe 
diarrhoea.
Articles
www.thelancet.com/lancetgh   Vol 8   February 2020 e210
ingesting only breastmilk] vs non-exclusive; see appendix 
p 57 for HRs when controlled for breastfeeding). Deaths 
in infants with tEPEC were clustered within the first 
3 months of life. In infants younger than 3 months who 
were not exclusively breastfed, the tEPEC isolation rate 
was twice as high (27 [17·2%] of 157) as it was in those 
who were exclusively breastfed (16 [7·1%] of 227; odds 
ratio 2·74, 95% CI 1·42–5·28; χ² p=0·0026).
Evidence of higher risk of death in children with non-
dysenteric MSD than in those with dysenteric MSD 
(tables 1 and 2), recognition that culture alone may miss 
Shigella spp infections detectable by qPCR, and qPCR 
data from a large random subset of cases from the GEMS 
study19 led us to analyse those data, including qPCR 
results for 153 (91·1%) of the 168 children with non-
dysenteric MSD who died in the GEMS study. 
Among 61 deaths in children aged 12–59 months who 
had non-dysenteric MSD, 31 occurred in 942 children who 
were Shigella-positive by qPCR and 30 deaths occurred in 
1384 children qPCR-negative for Shigella spp (HR 2·2, 
95% CI 1·2–3·9, p=0·0090 by Cox regression analysis). 
Thus, Shigella in children with non-dysenteric MSD was 
strongly associated with an increased risk of death. 
Notably, only eight (25·8%) of these 31 fatal infections 
positive for Shigella spp by qPCR were also positive by 
culture, while 23 (74·2%) were culture negative.
Altogether, 285 deaths occurred among cases or controls 
in the GEMS study (190 cases, 37 controls) and GEMS-1A 
study (45 cases, 13 controls), and verbal autopsy data were 
available for 266 (93·3%; table 4). Because verbal autopsy 
interpretation allowed death to have up to two co-primary 
diagnoses, total percentages exceeded 100%. Of 230 deaths 
with verbal autopsy results, 114 (49·6%) were attributed 
to diarrhoeal disease, 26 (11·3%) to sepsis, 19 (8·3%) to 
pneumonia or respiratory infections, and 21 (9·1%) to 
severe malnutrition. Most deaths could be categorised 
either as directly attributable to diarrhoeal disease or 
related to sequelae of diarrhoea, including malnutrition 
and increased risk of secondary bacterial infections.
Discussion
A hallmark observation from the GEMS study was that 
children with MSD had an 8·5 times higher likelihood of 
a fatal outcome during the approximately 60-day follow-
up period compared with control children without 
diarrhoea.12 This finding has now been corroborated by 
data from the GEMS-1A study (12 times increased risk of 
death in children with MSD vs matched controls). 
In the combined MSD dataset from the GEMS and 
GEMS-1A studies, approximately half of MSD-associated 
deaths occurred following discharge from the enrolment 
sentinel health centre and more than 2 weeks after 
enrolment, and would not have been detected had there 
not been the systematic single follow-up visit to the 
household at about 60 days after enrolment. These 
observations imply that within the reference population, 
MSD cases and their matched controls Non-dysenteric MSD cases and their matched 
controls
Dysenteric MSD cases and their matched 
controls
Cases Controls HR (95% CI) p value Cases Controls HR (95% CI) p value Cases Controls HR (95% CI) p value
The Gambia 47/1238 
(3·8%) 
8/2036 
(0·4%)
8·62 
(3·82–19·42)
<0·0001 36/897 
(4·0%)
8/1449 
(0·6%)
6·20 
(2·68–14·31)
<0·0001 11/341 
(3·2%)
0/587 ∞ ··
Mali 25/2430 
(1·0%)
5/2546 
(0·2%)
7·67 
(2·30–25·53)
<0·0009 22/2116 
(1·0%)
5/2222 
(0·2%)
6·67 
(1·98–22·44)
<0·0022 3/314 
(1·0%)
0/324 ∞ ··
Mozambique 59/725 
(8·1%)
13/1550 
(0·8%)
10·15 
(5·27–19·55)
<0·0001 56/588 
(9·5%)
13/1260 
(1·0%)
9·60 
(4·97–18·56)
<0·0001 3/137 
(2·2)
0/290 ∞ ··
Kenya 62/1718 
(3·6%)
14/2388 
(0·6%)
6·07 
(3·25–11·33)
<0·0001 59/1517 
(3·9%)
12/2087 
(0·6%)
7·05 
(3·59–13·85)
<0·0001 3/201 
(1·5%)
2/301 
(0·7%)
1·19 
(0·16–8·61)
0·087
India 2/2023 
(0·1%)
1/2522 
(<0·1%)
2·49* 
(0·33–19·02)
1·000 2/1764 
(0·1%)
1/2167 
(<0·1%)
2·46* 
(0·32–18·74)
1·000 0/259 0/355 ∞ ··
Bangladesh 7/1691 
(0·4%)
1/3153 
(<0·1%)
11·25 
(1·37–92·40)
0·024 6/400 
(1·5%)
0/760 ∞ ·· 1/1291 
(0·1%)
1/2393 
(<0·1%)
1·85* 
(0·20–17·74)
··
Pakistan 21/1283 
(1·6%)
1/2174 
(<0·1%)
16·00 
(2·12–120·65)
0·0071 18/982 
(1·8%)
1/1595 
(0·1%)
13·0 
(1·70–99·35)
0·0134 3/301 
(1·0%)
0/579 ∞ ··
All sites, age 0–59 months 223†/11 108 
(2·0%)
43/16 369 
(0·3%)
8·16 
(5·69–11·68)
<0·0001 199/8264 
(2·4%)
40/11 540 
(0·3%)
7·95 
(5·46–11·59)
<0·0001 24/2844 
(0·8%)
3/4829 
(0·1%)
10·38 
(3·08–34·96)
0·0002
All sites, age 0–11 months 125/4621 
(2·7%)
27/5978 
(0·5%)
6·42 
(4·10–10·06)
<0·0001 ·· ·· ·· ·· ·· ·· ·· ··
All sites, age 12–23 months 70/3768 
(1·9%)
13/5484 
(0·2%)
9·54 
(4·87–18·70)
<0·0001 ·· ·· ·· ·· ·· ·· ·· ··
All sites, age 24–59 months 28/2719 
(1·0%)
3/4907 
(0·1%)
22·47 
(5·29–95·41)
<0·0001 ·· ·· ·· ·· ·· ·· ·· ··
Data are number of deaths/total (%), unless otherwise stated. Also shown are the distributions of deaths in cases of MSD and deaths in controls by age stratum. MSD=moderate-to-severe diarrhoea. HR=hazard 
ratio. *Because of the small number of deaths, for these analyses a simple risk ratio was estimated by a likelihood score method rather than HR by Cox regression. †The 223 total deaths in children with MSD 
includes 97 (43·5%) girls and 126 (56·5%) boys, paralleling the enrolment distribution by sex of MSD cases (5280 [43·6%] girls, 6829 [56·4%] boys).
Table 1: Deaths among all MSD cases and non-dysenteric and dysenteric subgroups, and their matched controls, by site in both GEMS and GEMS-1A during 4 years of enrolment
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the burden of MSD-related deaths far exceeds deaths 
detected within the first days of onset of MSD episodes 
as observed in sentinel health centres.
Children with MSD in the GEMS-1A study had a 
significantly higher risk of death during the 60-day follow-
up period than did children with LSD, an observation that 
answers unequivocally the query about whether the 
GEMS definition of MSD truly encompasses illnesses 
with a greater likelihood of fatal outcome than LSD for 
the individual child.21 Nonetheless, findings from the 
GEMS-1A study also show that the risk of death in children 
with LSD is approximately 2·8 times higher than in 
controls without diarrhoea. A larger study with greater 
statistical power might have shown LSD to be significantly 
associated with risk of death. Consequently, for a similar 
number of deaths to accrue among LSD cases as among 
MSD cases, it would take approximately 2·5 times the 
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Dysenteric MSD cases
Controls
Cumulative deaths
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Figure 2: Cumulative hazard of death curves
Shaded areas represent 95% CIs. Cumulative hazard of death curves, number at risk, and cumulative deaths 
comparing all MSD cases compared with controls (A), non-dysenteric MSD cases compared with controls (B), and 
dysenteric MSD cases compared with controls (C) during the approximately 60-day follow-up period 
(range 50–90 days) for the seven GEMS and GEMS-1A sites, during 4 years of enrolment. Data are for children who 
had a follow-up visit within the 50–90-day window for the day-60 follow-up visit and for whom there was 
information about whether or not they had died. MSD=moderate-to-severe diarrhoea.
Number of deaths/
total* (%)
HR (95% CI) p value
GEMS MSD study
Cases 138†/7178 (1·9%) 8·89 
(5·55–14·22)
<0·0001
Controls 26†/10 548 (0·3%) 1 (ref) ··
GEMS MSD study
Dysenteric cases 19†/1952 (1·0%) 0·41 
(0·25–0·67)
0·0003
Non-dysenteric cases 119†/5226 (2·3%) 1 (ref) ··
GEMS-1A MSD study
Cases 23/2212 (1·0%) 11·91 
(3·50–40·53)
<0·0001
Controls 3/3433 (0·1%) 1 (ref) ··
GEMS-1A LSD study
Cases 12‡/2962 (0·4%) 2·78 
(0·95–8·11)
0·061
Controls 7/4074 (0·2%) 1 (ref) ··
GEMS-1A MSD study
Dysenteric cases 2/691 (0·3%) 0·20 
(0·05–0·87)
0·032
Non-dysenteric cases 21/1521 (1·4%) 1 (ref) ··
Intra-GEMS-1A comparison of MSD versus LSD
GEMS-1A MSD study 
cases
23/2212 (1·0%) 2·57 
(1·28–5·17)
0·0080
GEMS-1A LSD study 
cases
12‡/2962 (0·4%) 1 (ref) ··
Intra-GEMS-1A comparison of LSD versus non-dysenteric MSD
GEMS-1A LSD study 
cases
12‡/2962 (0·4%) 0·29 
(0·14–0·59)
0·0006
GEMS-1A MSD study 
non-dysenteric cases
21/1521 (1·4%) 1 (ref) ··
HR=hazard ratio. MSD=moderate-to-severe diarrhoea. LSD=less-severe diarrhoea. 
*The number of participants with follow-up information and therefore for whom 
health status (deceased or not) was known. †These numbers exclude GEMS MSD 
data from Kenya. ‡The 12 deaths in children with LSD include five (41·6%) girls 
and seven (58·3%) boys, paralleling the sex distribution of enrolled LSD cases 
(1492 [47·0%] girls, 1682 [53·0%] boys).
Table 2: Risk of death during 60 days of follow-up at six sites (The Gambia, 
Mali, Mozambique, India, Bangladesh, and Pakistan)
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number of LSD cases. Because the number of children 
with LSD attending sentinel health centres in the GEMS-
1A study was around three times the number of children 
with MSD, this implies that in the reference population 
more deaths overall occur in children with LSD.
Higher numbers of deaths occurred among controls 
in African sites than in Asian sites, reflecting the 
higher risk of death in children younger than 5 years in 
sub-Saharan Africa. Yet the highest risk of death in 
children with MSD was in Pakistan. In view of similar 
access to care and treatment regimens for MSD at all 
three Asian sites, we explored whether host nutritional 
differences (baseline nutritional state) might have 
contributed to the high risk of death in children with 
MSD in Pakistan. Indeed, children with MSD in Pakistan 
had significantly more linear growth faltering at baseline 
than did children with MSD in India and Bangladesh.
Several pathogens associated with increasing the 
risk of death from MSD in the GEMS study (ST-ETEC, 
tEPEC, and Cryptosporidium spp) were similarly identi-
fied in the GEMS-1A study, making these robust 
observations over multiple years of surveillance. ST-ETEC 
can rapidly dehydrate young infants leading to death, 
unless effective rehydration is promptly instituted. 
tEPEC and Crypto sporidium spp induce similar attaching 
and effacing histopathological lesions in small intestinal 
mucosa characterised by intimate adherence to entero-
cytes, effaced microvilli, and actin polymerisation;22–24 
gut dysfunction associated with these intestinal lesions 
might increase risk of death.20 Infants with tEPEC 
who died showed classic risk factors associated 
with severe and fatal disease (ie, early infancy and 
lack of exclusive breastfeeding).25 Other pathogens 
identified as increasing risk of death were Aeromonas 
Number of deaths with 
pathogen present/total (%)
Number of deaths with 
pathogen absent/total (%)
HR (95% CI) p value
0–11 months
Typical EPEC 29/431 (6·7%) 96/4190 (2·3%) 2·58 (1·69–3·93) <0·0001
ST/LT ETEC and ST-only ETEC 15/290 (5·2%) 110/4331 (2·5%) 1·92 (1·12–3·32) 0·019
Aeromonas spp 6/251 (2·4%) 119/4371 (2·7%) 3·28 (1·27–8·51) 0·015
12–23 months
Cryptosporidium spp 20/418 (4·8%) 50/3344 (1·5%) 2·14 (1·26–3·65) 0·0050
Typical EPEC 9/266 (3·4%) 61/3502 (1·7%) 2·35 (1·15–4·81) 0·019
Enteroaggregative Escherichia coli 19/645 (2·9%) 51/3123 (1·6%) 2·14 (1·24–3·70) 0·0063
Entamoeba histolytica 5/114 (4·4%) 65/3648 (1·8%) 3·46 (1·24–9·64) 0·018
Data include all 4 years of enrolment at seven sites during GEMS and GEMS-1A. MSD=moderate-to-severe diarrhoea. EPEC=enteropathogenic Escherichia coli. ST/LT 
ETEC=enterotoxigenic E coli encoding heat-stable toxin with co-expression of heat-labile enterotoxin. ST-only ETEC=enterotoxigenic E coli encoding heat-stable toxin 
without co-expression of heat-labile enterotoxin.
Table 3: Specific pathogens associated with a higher risk of fatal outcomes in infants and toddlers with MSD during GEMS and GEMS-1A, by age group
The Gambia Mali Mozambique Kenya India Bangladesh Pakistan Total
Number of deaths
GEMS deaths cases 39 23 51 52 2 7 16 190
GEMS deaths controls 7 5 11 11 1 1 1 37
GEMS-1A deaths cases 11 3 11 10 0 2 8 45
GEMS-1A deaths controls 3 1 3 3 1 1 1 13
Total deaths in study 60 32 76 76 4 11 26 285
Total deaths with verbal autopsy re-reviewed results 58 31 76 66 4 11 20 266
Discrepancies between physicians 8/58 (13·8%) 5/31 (16·1%) 20/76 (26·3%) 10/66 (15·2%) 0/4 0/11 7/20 (35·0%) 50/266 (18·8%)
Causes of death*
Diarrhoeal diseases (A09) 29/50 (58·0%) 15/26 (57·7%) 28/63 (44·4%) 22/55 (40·0%) 2/2 (100%) 8/9 (88·9%) 10/25 (40·0%) 114/230 (49·6%)
Acute respiratory infection, including pneumonia (J18) 4/50 (8·0%) 6/26 (23·1%) 4/63 (6·3%) 1/55 (1·8%) 1/2 (50·0%) 1/9 (11·1%) 3/25 (12·0%) 19/230 (8·3%)
HIV/AIDS-related death (B24) 0/50 1/26 (3·8%) 20/63 (31·7%) 21/55 38·2%) 0/2 0/9 0/25 42/230 (18·3%)
Severe malnutrition (E46) 14/50 (28·0%) 2/26 (7·7%) 2/63 (3·2%) 2/55 (3·6%) 1/2 (50·0%) 0/9 0/25 21/230 (9·1%)
Sepsis (including neonatal) (A41 and P36) 8/50 (16·0%) 4/26 (15·4%) 6/63 (9·5%) 0/55 0/2 5/9 (55·6%) 3/25 (12·0%) 26/230 (11·3%)
Malaria (B54) 3/50 (6·0%) 4/26 (15·4%) 2/63 (3·2%) 12/55 (21·8%) 0/2 0/9 1/25 (4·0%) 22/230 (9·6%)
*Causes of death (according to verbal autopsy) as primary or co-primary diagnosis (ICD-10 codes) in GEMS and GEMS-1A moderate-to-severe or less-severe diarrhoea cases only. Each patient may have up to 
two different diagnoses; therefore, numbers may exceed 100%.
Table 4: Results of the verbal autopsy re-examination exercise
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spp (infants) and E histolytica and enteroaggregative 
E coli (toddlers).
At first glance, a higher risk of death in children with 
non-dysenteric MSD than in those with dysenteric MSD 
might seem incongruous given the mucosal destruction 
that occurs with dysentery. However, dysentery (gross 
blood in diarrhoeal stools) is a clinical indication for 
treatment with anti-Shigella antibiotics, and most patients 
with dysenteric MSD in the GEMS and GEMS-1A studies 
received antibiotics. Thus, we hypothesise that antibiotic 
treatment lowered the risk of death from dysenteric MSD 
compared with non-dysenteric MSD. We also explored 
whether Shigella spp might be incriminated more strongly 
if we used molecular diagnostics rather than just culture, 
assuming the burden of Shigella spp in children with non-
dysenteric MSD is likely to be underestimated. In the 
GEMS study, we had qPCR data from a large random 
subset of cases and controls that allowed us to identify 
many Shigella-associated cases that had negative stool 
cultures.19 In children aged 12–59 months with non-
dysenteric MSD in the GEMS study, qPCR positivity for 
Shigella spp was strongly associated with increased risk 
of a fatal outcome. These data reinforce the need for 
Shigella vaccines and for an affordable, sensitive, and 
specific point-of-care test to diagnose Shigella spp in 
patients with non-dysenteric MSD to allow targeted, 
rational antibiotic treatment.
Because the occurrence of delayed (≥14 days post-
enrolment) MSD-associated deaths observed in the 
GEMS study has been substantiated by findings in the 
GEMS-1A study and an increased risk of death (albeit 
lower) has been observed in children with LSD, we must 
ponder what is responsible for the deaths. Causal 
pathways that could plausibly culminate in delayed 
fatality include (1) dehydration worsening or recurring 
after discharge from the sentinel health centre, inadequate 
oral rehydration at home, and failure to return the child 
promptly to health care; (2) bacteraemia secondary to 
mucosal injury triggering over-stimulation of the systemic 
innate immune system leading to systemic inflammatory 
response syndrome (also known as sepsis syndrome);26 
(3) gut microbiome alterations consequent to MSD and 
LSD allowing translocation and bloodstream invasion by 
opportunistic bacterial pathogens even if the intestinal 
mucosa remains intact, whereupon clinical sepsis can 
ensue; (4) severe gut dysfunction resulting in mal-
absorption and anorexia, leading to malnutrition, 
micronutrient deficiency and, ultimately, death; (5) rarely, 
progression to persistent diarrhoea, a harbinger for fatal 
outcomes;27 and (6) an increased risk of pneumonia or 
other severe infections following diarrhoeal disease.28
Analysis of verbal autopsy data from children who died 
in the African and Asian sites of the GEMS study shows 
that the most attributed causes of death coincide with the 
above possibilities, even if information for the Asian 
sites is limited because of the scarcer number of deaths 
occurring there. Nevertheless, verbal autopsy, while 
valuable, is an imperfect tool for interpreting the cause of 
death at the individual level. More definitive investigative 
tools are needed.29 Underlying HIV-1 infection, malaria, 
or severe malnutrition might render children more 
susceptible to fatality following MSD or LSD, whatever 
the aetiological agent responsible for their diarrhoea. It is 
hoped that the evidence of delayed deaths following 
MSD and LSD will stimulate innovative clinical and 
epidemiological investigations to elucidate the major 
precipitating causes of death, so that interventions can be 
designed and evaluated.
One limitation of the GEMS and GEMS-1A studies 
is that although rotavirus was documented as the 
predominant pathogen responsible for MSD and LSD 
morbidity, because enrolment was done at sentinel 
health centres in which effective rehydration therapy was 
available to replace water and electrolyte deficits, deaths 
from rotavirus dehydration were uncommon. However, 
without access to health care, many infants or toddlers 
with rotavirus diarrhoeal dehydration would surely have 
died. Rotavirus aside, for groups estimating global 
diarrhoeal disease mortality by aetiology,8 the data from 
the GEMS and GEMS-1A studies reported here allow 
for improved disaggregation by severity, and direct 
estimation of population-based (vs hospital-based) risk of 
death due to MSD and LSD.8
The risk of death analyses in this study can help public 
health decision makers choose what invest ments to 
make among competing priorities. Our data emphasise 
the value of preventing or treating all diarrhoeal syndromes 
that bring children to health care, including LSD and 
MSD. Because the major attributable enteric pathogens 
associated with LSD and MSD are the same,12,16 a public 
health argument can be made to avert the cascade of 
adverse events that follow MSD and LSD by primary 
prevention of illnesses caused by certain major attributed 
pathogens. One action would be to facilitate future 
implementation of vaccines against Shigella spp and ETEC 
that are currently in clinical development. Because 
vaccines against Cryptosporidium spp remain a distant 
goal,30 alternative strategies must diminish the ravages of 
that pathogen. One strategy would be to develop affordable 
point-of-care diagnostics to detect children infected with 
Cryptosporidium spp and safe, effective therapeutics to treat 
their infections. Collectively, such interventions can help to 
assure that by 2030 diarrhoeal disease will no longer be a 
major cause of death in children younger than 5 years in 
any resource-scarce, impover ished setting.7
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